首页/数据集/Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

NCATS Open Data2022-06-03 更新2026-08-08 收录

异源加强免疫

RBD-mRNA疫苗临床试验

数据链接：

https://doi.org/10.1101/2022.05.30.22275753 数据链接链接失效反馈

官方服务：

资源简介：

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

应用场景：

创建时间：

2022-05-31

异源加强免疫

COVID-19疫苗效果评估

The development and deployment of vaccines have played a critical role in the control and management of the COVID-19 pandemic. Although homologous vaccination regimens (i.e. vaccinations where individ

NIAID Data Ecosystem10

Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study

疫苗效果评估

异源加强免疫

Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak of SARS-CoV-2 omicron predominance in China has not b

Taylor & Francis Group2024-12-07 更新00

Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report.

疫苗临床试验

异源加强免疫

Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report.

NCATS Open Data2023-01-20 更新00

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial

COVID-19

异源加强免疫

NCATS Open Data2022-03-04 更新00